Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iris Breitkreutz

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|July 16, 2008
Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicityIris Breitkreutz, Kenneth C Anderson
Lancet (London, England)|June 23, 2009
Multiple myelomaMarc S Raab, Klaus Podar, Iris Breitkreutz, et al.
Annals of Hematology|January 24, 2018
The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myelomaIris Breitkreutz, Klaus Podar, Vianihuini Figueroa-Vazquez, et al.
Blood Cancer Journal|August 27, 2024
Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significanceKosima Zuern, Thomas Hielscher, Annika Werly, et al.
Hematological Oncology|March 19, 2015
Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow functionIris Breitkreutz, Natalia Becker, Axel Benner, et al.
British Journal of Haematology|September 15, 2007
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myelomaIris Breitkreutz, Marc S Raab, Sonia Vallet, et al.
Haematologica|November 4, 2006
The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failureMarc S Raab, Iris Breitkreutz, Michael Hundemer, et al.
Cancers|September 28, 2021
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple MyelomaMarc-Andrea Baertsch, Mathilde Fougereau, Thomas Hielscher, et al.
Blood|October 7, 2006
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)Klaus Podar, Marc S Raab, Jing Zhang, et al.
Oncotarget|October 10, 2014
Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1Verena Wagner, Dirk Hose, Anja Seckinger, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Expert Opinion on Drug Metabolism & Toxicology|July 16, 2008
Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicityIris Breitkreutz, Kenneth C Anderson
Lancet (London, England)|June 23, 2009
Multiple myelomaMarc S Raab, Klaus Podar, Iris Breitkreutz, et al.
Annals of Hematology|January 24, 2018
The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myelomaIris Breitkreutz, Klaus Podar, Vianihuini Figueroa-Vazquez, et al.
Blood Cancer Journal|August 27, 2024
Longitudinal assessment of established risk stratification models in patients with monoclonal gammopathy of undetermined significanceKosima Zuern, Thomas Hielscher, Annika Werly, et al.
Hematological Oncology|March 19, 2015
Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow functionIris Breitkreutz, Natalia Becker, Axel Benner, et al.
British Journal of Haematology|September 15, 2007
Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myelomaIris Breitkreutz, Marc S Raab, Sonia Vallet, et al.
Haematologica|November 4, 2006
The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failureMarc S Raab, Iris Breitkreutz, Michael Hundemer, et al.
Cancers|September 28, 2021
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Salvage Autologous Stem Cell Transplant with or without Maintenance for Relapsed or Refractory Multiple MyelomaMarc-Andrea Baertsch, Mathilde Fougereau, Thomas Hielscher, et al.
Blood|October 7, 2006
Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl)Klaus Podar, Marc S Raab, Jing Zhang, et al.
Oncotarget|October 10, 2014
Preclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1Verena Wagner, Dirk Hose, Anja Seckinger, et al.
Pageof 2